双相情感障碍治疗中的药理学问题：聚焦于心境稳定剂类化合物。
Pharmacological issues in the treatment of bipolar disorder: focus on mood-stabilizing compounds.
作者信息
Potter W Z, Ketter T A
机构信息
Section on Clinical Pharmacology, National Institute of Mental Health, Bethesda, Maryland 20892.
出版信息
Can J Psychiatry. 1993 Apr;38(3 Suppl 2):S51-6.
The acute and chronic pharmacotherapy of bipolar disorder requires an understanding of the pharmacology of very dissimilar compounds--the mood stabilizers (lithium, carbamazepine and valproate) and several classes of antidepressants. No definitive data are available on the primary mode of action of mood stabilizers, and those used show no single pharmacological property. On the other hand, the pharmacokinetics and dynamics of these compounds are well studied.
双相情感障碍的急性和慢性药物治疗需要了解非常不同的化合物的药理学——心境稳定剂（锂盐、卡马西平和丙戊酸盐）以及几类抗抑郁药。关于心境稳定剂的主要作用方式尚无确切数据，而且所使用的心境稳定剂没有单一的药理学特性。另一方面，这些化合物的药代动力学和药效学已得到充分研究。
Zotero 插件